Fig. 2: Higher DAM2 markers protect against future tau accumulation and cognitive decline in individuals with AD pathology. | Nature Aging

Fig. 2: Higher DAM2 markers protect against future tau accumulation and cognitive decline in individuals with AD pathology.

From: Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology

Fig. 2

a–k, Results of the linear mixed effect models showing that nondemented A+T+ individuals with higher baseline DAM2 marker levels show lower longitudinal accumulation of tau aggregates in III–IV (a,c,e,g) and V–VI (b,d,f,h) Braak regions (GAS6: n = 38; CSF1: n = 37; CST7: n = 37; SPP1: n = 38; MERKT: n = 37) as well as a decline in the MMSE test scores (MERKT: n = 51; CST7: n = 51) (i,j), except for the SPP1 DAM2 marker, which showed the opposite results (n = 52) (g,k). Amyloid (A+) and tau (T+) pathology were assessed using PET. All variables were z-transformed (Z), and the results were adjusted for multiple comparisons using FDR corrections (two tailed, q < 0.05). Data are presented as the mean ± s.e.m.

Back to article page